Cargando…

Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review

RNA modifications are mostly dynamically reversible post-transcriptional modifications, of which m6A is the most prevalent in eukaryotic mRNAs. A growing number of studies indicate that RNA modification can finely tune gene expression and modulate RNA metabolic homeostasis, which in turn affects the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zujian, Sheng, Jingjing, Hu, Yingying, Zhang, Yu, Wang, Xiaoxia, Huang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598767/
https://www.ncbi.nlm.nih.gov/pubmed/37886684
http://dx.doi.org/10.3389/fgene.2023.1247309
_version_ 1785125627790098432
author Jin, Zujian
Sheng, Jingjing
Hu, Yingying
Zhang, Yu
Wang, Xiaoxia
Huang, Yiping
author_facet Jin, Zujian
Sheng, Jingjing
Hu, Yingying
Zhang, Yu
Wang, Xiaoxia
Huang, Yiping
author_sort Jin, Zujian
collection PubMed
description RNA modifications are mostly dynamically reversible post-transcriptional modifications, of which m6A is the most prevalent in eukaryotic mRNAs. A growing number of studies indicate that RNA modification can finely tune gene expression and modulate RNA metabolic homeostasis, which in turn affects the self-renewal, proliferation, apoptosis, migration, and invasion of tumor cells. Endometrial carcinoma (EC) is the most common gynecologic tumor in developed countries. Although it can be diagnosed early in the onset and have a preferable prognosis, some cases might develop and become metastatic or recurrent, with a worse prognosis. Fortunately, immunotherapy and targeted therapy are promising methods of treating endometrial cancer patients. Gene modifications may also contribute to these treatments, as is especially the case with recent developments of new targeted therapeutic genes and diagnostic biomarkers for EC, even though current findings on the relationship between RNA modification and EC are still very limited, especially m6A. For example, what is the elaborate mechanism by which RNA modification affects EC progression? Taking m6A modification as an example, what is the conversion mode of methylation and demethylation for RNAs, and how to achieve selective recognition of specific RNA? Understanding how they cope with various stimuli as part of in vivo and in vitro biological development, disease or tumor occurrence and development, and other processes is valuable and RNA modifications provide a distinctive insight into genetic information. The roles of these processes in coping with various stimuli, biological development, disease, or tumor development in vivo and in vitro are self-evident and may become a new direction for cancer in the future. In this review, we summarize the category, characteristics, and therapeutic precis of RNA modification, m6A in particular, with the purpose of seeking the systematic regulation axis related to RNA modification to provide a better solution for the treatment of EC.
format Online
Article
Text
id pubmed-10598767
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105987672023-10-26 Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review Jin, Zujian Sheng, Jingjing Hu, Yingying Zhang, Yu Wang, Xiaoxia Huang, Yiping Front Genet Genetics RNA modifications are mostly dynamically reversible post-transcriptional modifications, of which m6A is the most prevalent in eukaryotic mRNAs. A growing number of studies indicate that RNA modification can finely tune gene expression and modulate RNA metabolic homeostasis, which in turn affects the self-renewal, proliferation, apoptosis, migration, and invasion of tumor cells. Endometrial carcinoma (EC) is the most common gynecologic tumor in developed countries. Although it can be diagnosed early in the onset and have a preferable prognosis, some cases might develop and become metastatic or recurrent, with a worse prognosis. Fortunately, immunotherapy and targeted therapy are promising methods of treating endometrial cancer patients. Gene modifications may also contribute to these treatments, as is especially the case with recent developments of new targeted therapeutic genes and diagnostic biomarkers for EC, even though current findings on the relationship between RNA modification and EC are still very limited, especially m6A. For example, what is the elaborate mechanism by which RNA modification affects EC progression? Taking m6A modification as an example, what is the conversion mode of methylation and demethylation for RNAs, and how to achieve selective recognition of specific RNA? Understanding how they cope with various stimuli as part of in vivo and in vitro biological development, disease or tumor occurrence and development, and other processes is valuable and RNA modifications provide a distinctive insight into genetic information. The roles of these processes in coping with various stimuli, biological development, disease, or tumor development in vivo and in vitro are self-evident and may become a new direction for cancer in the future. In this review, we summarize the category, characteristics, and therapeutic precis of RNA modification, m6A in particular, with the purpose of seeking the systematic regulation axis related to RNA modification to provide a better solution for the treatment of EC. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598767/ /pubmed/37886684 http://dx.doi.org/10.3389/fgene.2023.1247309 Text en Copyright © 2023 Jin, Sheng, Hu, Zhang, Wang and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Jin, Zujian
Sheng, Jingjing
Hu, Yingying
Zhang, Yu
Wang, Xiaoxia
Huang, Yiping
Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title_full Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title_fullStr Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title_full_unstemmed Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title_short Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review
title_sort shining a spotlight on m6a and the vital role of rna modification in endometrial cancer: a review
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598767/
https://www.ncbi.nlm.nih.gov/pubmed/37886684
http://dx.doi.org/10.3389/fgene.2023.1247309
work_keys_str_mv AT jinzujian shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview
AT shengjingjing shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview
AT huyingying shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview
AT zhangyu shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview
AT wangxiaoxia shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview
AT huangyiping shiningaspotlightonm6aandthevitalroleofrnamodificationinendometrialcancerareview